Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST
A structure-based scaffold-hopping strategy to design kinase inhibitors with selectivity for mutant KIT/PDGFRA and the PDGFRA-G680R structure shows the molecular basis for targeting solvent-front mutations across oncogenic kinases.